Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
暂无分享,去创建一个
J J Schentag | A Forrest | Jerome J. Schentag | T. Goss | A. Forrest | D. Nix | C. Ballow | M. Birmingham | C H Ballow | D E Nix | T F Goss | M C Birmingham
[1] R. Auckenthaler,et al. Combination therapy: a way to limit emergence of resistance? , 1986, The American journal of medicine.
[2] R. Chaisson,et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. , 1991, The New England journal of medicine.
[3] Jerome J. Schentag,et al. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. , 1987, The American journal of medicine.
[4] H. Neu,et al. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. , 1981, JAMA.
[5] H. Neu. Bacterial resistance to fluoroquinolones. , 1988, Reviews of infectious diseases.
[6] I. L. Smith,et al. Role for dual individualization with cefmenoxime. , 1984, The American journal of medicine.
[7] Jerome J. Schentag,et al. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response , 1991, Antimicrobial Agents and Chemotherapy.
[8] L. Peterson,et al. Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. , 1986, The Journal of antimicrobial chemotherapy.
[9] P. Gerner-Smidt,et al. Analysis of the interaction between piperacillin and ciprofloxacin or tobramycin against thirteen strains of Pseudomonas aeruginosa, using killing curves. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section B, Microbiology.
[10] J F Boisvieux,et al. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. , 1984, Drug metabolism reviews.
[11] Dan Steinberg,et al. Survival: A Supplementary Module for SYSTAT , 1989 .
[12] J. S. Wolfson,et al. SERUM BACTERICIDAL ACTIVITY AS A MONITOR OF ANTIBIOTIC THERAPY , 1985 .
[13] T. Rogers,et al. A randomized trial of ciprofloxacin plus azlocillin versus netilmicin plus azlocillin for the empirical treatment of fever in neutropenic patients. , 1991, The Journal of antimicrobial chemotherapy.
[14] H. Neu,et al. ORAL CIPROFLOXACIN THERAPY OF INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA , 1986, The Lancet.
[15] S. Barriere,et al. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. , 1985, The Journal of antimicrobial chemotherapy.
[16] R. Goering,et al. Overview of preclinical studies with ciprofloxacin. , 1987, The American journal of medicine.
[17] D. Hooper,et al. Bacterial resistance to quinolones: mechanisms and clinical importance. , 1989, Reviews of infectious diseases.
[18] Jerome J. Schentag,et al. Liquid-chromatographic determination of ciprofloxacin in serum and urine. , 1985, Clinical chemistry.
[19] Jerome J. Schentag,et al. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning , 1991, Antimicrobial Agents and Chemotherapy.
[20] Jerome J. Schentag. Clinical Significance of Antibiotic Tissue Penetration , 1989, Clinical pharmacokinetics.
[21] H. Koornhof,et al. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions , 1985, Antimicrobial Agents and Chemotherapy.
[22] R. Jelliffe,et al. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight , 1972 .
[23] M. Bergeron. The pharmacokinetics and tissue penetration of the fluoroquinolones. , 1989, Clinical and investigative medicine. Medecine clinique et experimentale.
[24] C. Stratton,et al. Comparison of the bactericidal activity of ciprofloxacin alone and in combination with selected antipseudomonal beta-lactam agents against clinical isolates of Pseudomonas aeruginosa. , 1988, Diagnostic microbiology and infectious disease.
[25] G. Eliopoulos,et al. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent , 1984, Antimicrobial Agents and Chemotherapy.
[26] Jerome J. Schentag. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. , 1990, Scandinavian journal of infectious diseases. Supplementum.
[27] A. Gerber,et al. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. , 1986, The Journal of infectious diseases.
[28] J. Righter. Ciprofloxacin treatment of Staphylococcus aureus infections. , 1987, The Journal of antimicrobial chemotherapy.
[29] O. Cars. Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. , 1990, Scandinavian journal of infectious diseases. Supplementum.
[30] Jerome J. Schentag,et al. Dose-Ranging Pharmacokinetic Study of Ciprofloxacin after 200-, 300-, and 400-mg Intravenous Doses , 1992, The Annals of pharmacotherapy.
[31] Jerome J. Schentag,et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin , 1993, Antimicrobial Agents and Chemotherapy.
[32] Jerome J. Schentag,et al. Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin , 1991, DICP : the annals of pharmacotherapy.